Health & Biotech
Health Check: It’s ‘nothing personal’ as major US biotech fund calls time on Syntara
Optiscan teams up with US-based Long Grove Pharmaceuticals
Trajan delivering precision to global science, one component at a time
Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential
Criterion: Back up the dumpster! It’s time for an EOFY share purge
There’s been a new outbreak in Sydney, so what exactly is Legionnaires’ disease?
Scott Power: ASX health stocks fall in ‘lacklustre week’
Medtech start-up IMRA cap raises to expand realistic human models for robotic surgery training
Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Orthocell sets new benchmark in nerve repair
Health Check: Mayne Pharma shareholders back $600m ‘phantom’ takeover offer
Biocurious: Rhythm gets into the groove of predicting and preventing cancer
Lumos’ FebriDx joins trial of antibiotic prescribing by GPs for respiratory infections
Recce secures $30m debt facility to support Phase III trials
Health Check: In shunning the IPO hot money, Tetratherix says ‘less is more’
Dr Boreham’s Crucible: Sizing up the opportunity for ASX biotech Adherium
Positive preclinical data supports potential of Neurizon’s NUZ-001 in Huntington’s disease
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
